Blood News and Research RSS Feed - Blood News and Research

DNA Diagnostics Center launches new Paternity Test Kit

DNA Diagnostics Center launches new Paternity Test Kit

DNA Diagnostics Center, the world's largest DNA Paternity Testing Company, announces the launch of a new Paternity Test Kit to be sold in national retail stores, expanding the company's reach in the marketplace. [More]
Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
Research finding opens door to potential treatment for MPS IIIB

Research finding opens door to potential treatment for MPS IIIB

MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death -- often before reaching adulthood. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Researchers explain how molecular structure of the heart muscle changes in heart failure

Researchers explain how molecular structure of the heart muscle changes in heart failure

In a new study published in Proceedings of the National Academy of Sciences USA, researchers at the University of Alberta's Faculty of Medicine & Dentistry have explained how the function of a key protein in the heart changes in heart failure. [More]
State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

Health insurance policies in California will have to cover all federally approved contraceptives for women by 2016 without charging co-payments under legislation signed this week by Gov. Jerry Brown, countering trends in other states and the U.S. Supreme Court. The bill, SB1053 by Sen. Holly Mitchell, D-Los Angeles, expands state laws that required coverage for most birth-control drugs and devices approved by the U.S. Food and Drug Administration. The new law mandates coverage for all FDA-approved contraception, prohibits co-payments and includes managed-care Medi-Cal plans, which are not expressly covered by current laws (Egelko, 9/27). [More]
Finding ways to rejuvenate "immunological age" of the brain

Finding ways to rejuvenate "immunological age" of the brain

How the brain ages is still largely an open question - in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. [More]
Specific nurse-to-patient staffing standards lower job-related injuries, illnesses for nurses

Specific nurse-to-patient staffing standards lower job-related injuries, illnesses for nurses

A 2004 California law mandating specific nurse-to-patient staffing standards in acute care hospitals significantly lowered job-related injuries and illnesses for both registered nurses and licensed practical nurses, according to UC Davis research published online in the International Archives of Occupational and Environmental Health. [More]
Increasing prevalence of obstructive sleep apnea threatens public health and safety

Increasing prevalence of obstructive sleep apnea threatens public health and safety

Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the U.S., according to the National Healthy Sleep Awareness Project. Several new studies highlight the destructive nature of obstructive sleep apnea, a chronic disease that increases the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and depression. [More]
Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma. [More]
Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd. [More]
Cancer specialist outlines 10 symptoms that should never be ignored

Cancer specialist outlines 10 symptoms that should never be ignored

Patients often ask, "Doc, is this something to worry about?" Patients fear the worst yet often choose to ignore potentially deadly warning signs. [More]
Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration. [More]
Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. [More]
Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain. [More]
EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Early detection of cancers on the horizon with supersensitive nanodevice

Early detection of cancers on the horizon with supersensitive nanodevice

Extremely early detection of cancers and other diseases is on the horizon with a supersensitive nanodevice being developed at The University of Alabama in Huntsville in collaboration with The Joint School of Nanoscience and Nanoengineering in Greensboro, NC. [More]
ED more prevalent than previously thought

ED more prevalent than previously thought

Specialists in treatment of erectile dysfunction recognize that ED is more prevalent than previously recognized. [More]